Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
5(50.0%)
Phase 1
4(40.0%)
Early Phase 1
1(10.0%)
10Total
Phase 2(5)
Phase 1(4)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT04005690Early Phase 1Recruiting

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Role: collaborator

NCT05383196Phase 1Active Not Recruiting

Onvansertib + Paclitaxel In TNBC

Role: collaborator

NCT06106308Phase 2Active Not Recruiting

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Role: lead

NCT04752696Phase 2Completed

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

Role: lead

NCT05450965Phase 2Recruiting

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Role: collaborator

NCT03829410Phase 1Completed

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Role: lead

NCT06736717Phase 1Recruiting

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Role: collaborator

NCT05593328Phase 2Completed

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Role: lead

NCT03414034Phase 2Completed

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Role: lead

NCT04446793Unknown

Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

Role: lead

NCT03303339Phase 1Completed

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

Role: lead

NCT02186236Completed

Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients

Role: collaborator

All 12 trials loaded